Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Synovial Sarcoma Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Synovial Sarcoma Overview | 9 | 1 |
| Pipeline Products for Synovial Sarcoma Comparative Analysis | 10 | 1 |
| Synovial Sarcoma Therapeutics under Development by Companies | 11 | 1 |
| Synovial Sarcoma Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Synovial Sarcoma Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Synovial Sarcoma Products under Development by Companies | 16 | 1 |
| Synovial Sarcoma Products under Investigation by Universities/Institutes | 17 | 1 |
| Synovial Sarcoma Companies Involved in Therapeutics Development | 18 | 12 |
| Adaptimmune Therapeutics Plc | 18 | 1 |
| Advenchen Laboratories, LLC | 19 | 1 |
| EpiZyme, Inc. | 20 | 1 |
| Immune Design Corp. | 21 | 1 |
| Immunocore Limited | 22 | 1 |
| Karyopharm Therapeutics, Inc. | 23 | 1 |
| Merck &Co., Inc. | 24 | 1 |
| Millennium Pharmaceuticals Inc | 25 | 1 |
| Novartis AG | 26 | 1 |
| OncoTherapy Science, Inc. | 27 | 1 |
| Pfizer Inc. | 28 | 1 |
| Takara Bio Inc. | 29 | 1 |
| Synovial Sarcoma Therapeutics Assessment | 30 | 9 |
| Assessment by Monotherapy Products | 30 | 1 |
| Assessment by Target | 31 | 2 |
| Assessment by Mechanism of Action | 33 | 2 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Drug Profiles | 39 | 95 |
| ACXT-3102 Drug Profile | 39 | 1 |
| AL-3818 Drug Profile | 40 | 3 |
| axitinib Drug Profile | 43 | 6 |
| Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile | 49 | 1 |
| CMB-305 Drug Profile | 50 | 3 |
| everolimus Drug Profile | 53 | 12 |
| GSK-3377794 Drug Profile | 65 | 6 |
| OTSA-101 Drug Profile | 71 | 1 |
| pembrolizumab Drug Profile | 72 | 31 |
| Recombinant Protein for Oncology Drug Profile | 103 | 1 |
| Recombinant Proteins 1 for Oncology Drug Profile | 104 | 1 |
| sapanisertib Drug Profile | 105 | 3 |
| selinexor Drug Profile | 108 | 17 |
| SSTC-104 Drug Profile | 125 | 1 |
| tazemetostat Drug Profile | 126 | 7 |
| TBI-1301 Drug Profile | 133 | 1 |
| Synovial Sarcoma Discontinued Products | 134 | 1 |
| Synovial Sarcoma Product Development Milestones | 135 | 5 |
| Featured News &Press Releases | 135 | 1 |
| Feb 22, 2016: The completion of phase I clinical study of the anti-cancer therapeutic antibody OTSA101 against synovial sarcoma | 135 | 1 |
| Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors | 135 | 1 |
| Aug 24, 2015: Epizyme Announces Acceptance of Investigational New Drug Application for Tazemetostat in Patients with INI1-Negative Tumors or Synovial Sarcoma | 136 | 2 |
| Oct 17, 2014: Epizyme Presents Pre-Clinical Data on EZH2 Inhibitor EPZ-6438 (E7438) in Models of Synovial Sarcoma | 138 | 1 |
| Jul 30, 2012: OncoTherapy Science Receives Patent For OTSA101 In Japan And US | 139 | 1 |
| Oct 16, 2011: OncoTherapy Science's Subsidiary Receives French Approval For Clinical Trial Of OTSA101 | 139 | 1 |
| Appendix | 140 | 2 |
| Methodology | 140 | 1 |
| Coverage | 140 | 1 |
| Secondary Research | 140 | 1 |
| Primary Research | 140 | 1 |
| Expert Panel Validation | 140 | 1 |
| Contact Us | 140 | 1 |
| Disclaimer | 141 | 1 |